middle.news
Paradigm Biopharma Secures US$5M to Accelerate Global Phase 3 Trial Expansion
12:31pm on Monday 17th of November, 2025 AEDT
•
Healthcare
Read Story
Paradigm Biopharma Secures US$5M to Accelerate Global Phase 3 Trial Expansion
12:31pm on Monday 17th of November, 2025 AEDT
Key Points
US$5 million drawdown completed under US$27 million convertible note facility
Funding supports global Phase 3 trial of injectable pentosan polysulfate sodium (iPPS)
Operational expansion includes accelerated site activations and patient recruitment in US, Australia, Europe, and Asia
US$15 million remains available to support ongoing clinical and commercial activities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE